Floatz logo

Rucacuzumab

Acute Ischemic Stroke AIS

Peking Union Medical College HospitalPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

210 Active assets in the Acute Ischemic Stroke AIS cohort.

Asset / SponsorPhaseRating
Ticagrelor
Sichuan Provincial People's Hospital
Phase 4BBB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Stanford University
Phase 4BBB
Compound Edaravone
Nanfang Hospital, Southern Medical University
Phase 4BBB
Argatroban
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Tenecteplase
Hackensack Meridian Health
Phase 4BBB

View all 50 →

Same molecule, other indications

Rucacuzumab is also rated in:

cerebral atherosclerosisDormant
BB
Indicative ·
65 / 100
View asset →
atherosclerosisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →